Roche released an announcement today in regards to its phase three trial called EMILIA. The program compared performance of its new drug Trastuzumab Emtansine against standard treatments for HER2-positive Metastatic Breast Cancer that use lapatinib plus Xeloda® (capecitabine). Patients were...